Among the medicines listed for Multiple Myeloma; MDS; Lymphoma, Lenalidomide has a defined role in Multiple myeloma; myelodysplastic syndrome with del(5q); selected lymphomas. Immunomodulatory drug that alters cereblon-dependent protein degradation, cytokine signaling and tumor-cell survival. Its pharmacological class is IMiD. The pharmacologic action described for this medicine provides the basis for its use in the malignancies and treatment settings listed in the database. The database categorizes it as Targeted Therapy; Immunomodulatory Agent and records regimen examples such as VRd; Rd; Dara-Rd; maintenance after autologous transplant; lymphoma combinations. These combinations indicate how the agent fits into broader treatment programs rather than functioning as a universal therapy for every cancer in the tumor group. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. Clinical interpretation should include the disease stage, histology, treatment history, and any molecular or receptor feature expressly named in the indication. The mechanism is useful for understanding why those selection criteria matter and why another drug from the same broad category may not be interchangeable. This summary has been written for an oncology medicines reference database and does not attempt to prescribe therapy for an individual patient. Because labels and guideline-supported uses can change, current product information should be checked when the entry is applied clinically.